NTRK1 and cancer: Targeted therapy of cancer by specific inhibition of aberrantly activated receptor tyrosine kinase (RTK) activities in cancer cells with chemically synthesized small molecule compounds, tyrosine kinase inhibitors (TKIs), shows better responses while less side effects than traditional chemotherapeutic drugs.